Follicular Lymphoma | Clinical

Duvelisib for R/R Follicular Lymphoma Voluntarily Pulled from the US Market

December 06, 2021

The post-marketing requirements for duvelisib are no longer necessary, according to the FDA, and the agent has been withdrawn from the United States market for the treatment of patients with relapsed or refractory follicular lymphoma.

FDA Considers Parsaclisib for Approval in FL, MZL, and MCL

November 01, 2021

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.